Novo Nordisk sets U.S. launch price for oral Ozempic, targeting insured patients

Novo Nordisk just turned Ozempic into a much more direct access play in the U.S. The company began rolling out oral Ozempic on May 4 in three doses — 1.5 mg, 4 mg, and 9 mg — with a pricing setup built to make the insured option look almost frictionless. Most insured patients may pay as little as $25 for up to a three-month prescription, while cash-pay pricing starts at $149 a month. That matters because the big gap in GLP-1s has never just been demand — it has been cost, coverage, and the fact that a lot of people do not want an injection. ### What actually launched? This is not a brand-new molecule. It is semaglutide — the same core drug family behind Ozempic and Wegovy — but in a pill form for adults with type 2 diabetes. Novo says the tablets are now moving through more than 70,000 U.S. pharmacies, and the oral version carries the Ozempic brand instead of staying under the older Rybelsus name. Basically, Novo is taking a drug people already know and trust, then making the format easier to accept for patients who would rather swallow a pill than start a weekly shot. ### Why does the $25 number matter so much? Because it is the headline number doctors and patients will remember. Novo says most insured patients can get oral Ozempic for as little as $25 for as much as a three-month fill. That is a very aggressive signal. It tells prescribers, “don’t assume the pill is the premium convenience version.” But the catch is that this is the insured path. For people paying cash, the monthly list through NovoCare Pharmacy and partner channels is $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg. ### Why not just keep selling Rybelsus? Brand power. Ozempic is one of the best-known drug names in America. Rybelsus never had that kind of cultural or prescribing pull. So Novo is collapsing the message — injection or pill, same umbrella brand, same semaglutide story. That makes the sales pitch simpler for clinicians and less confusing for patients. It also gives Novo a cleaner defense as Eli Lilly pushes harder in oral GLP-1s. ### What is different medically? The biggest clinical hook is not just glucose control. Novo says oral Ozempic is the only FDA-approved oral peptide GLP-1 for adults with type 2 diabetes that also carries cardiovascular risk-reduction language for high-risk patients. That is a real distinction, because diabetes drugs increasingly compete on heart outcomes, not just A1C. In plain English — the pill is being positioned as more than a convenience reformulation. Novo wants it seen as a full-strength cardiometabolic product. ### Why launch now? Competition. Lilly has been gaining momentum in the broader GLP-1 market, and investors are watching whether Novo can keep prescription growth up while prices get more contested. A pill helps because it opens a different patient pool — people earlier in treatment, people hesitant about injections, and people whose doctors want an easier first step. ### What is the next shoe to drop? Novo has also filed for a 25 mg tablet and expects an FDA decision by the end of 2026. If that gets cleared, the company gets a stronger oral ladder — starter, maintenance, and then potentially a higher-dose option that could make the pill line more competitive inside diabetes treatment and maybe more strategically useful beyond it. ### Bottom line? This launch is really about reducing refusal points. Not just “here is Ozempic in a pill,” but “here is Ozempic in a pill, under the familiar brand, in lots of pharmacies, with an insured price low enough to get people moving.” If that works, Novo is not merely extending a franchise — it is trying to turn oral GLP-1s into the easier front door.